1. 2017 EDS International Classification | The Ehlers Danlos Society : The Ehlers Danlos Society.
Available at: https://www.ehlers-danlos.com/2017-eds-international-classification
2. Pepin,
M.,
Schwarze,
U.,
Superti-Furga,
A.
& Byers,
P.
H.
Clinical and Genetic Features of Ehlers–Danlos Syndrome Type IV,
the Vascular Type. N.
Engl.
J.
Med.342,673–680 (2000).
3. Halper,
J. Progress in heritable soft connective tissue diseases.
4. Murray,
M.
L.,
Pepin,
M.,
Peterson,
S.
& Byers,
P.
H.
Pregnancy-related deaths and complications in women with vascular Ehlers–Danlos syndrome. Genet.
Med.16,874–880 (2014).
5. Ong,
K.-T. et al.Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised,
open,
blinded-endpoints trial. Lancet (London,
England)376,1476–84 (2010).
6. Lum,
Y.
W.,
Brooke,
B.
S.,
Arnaoutakis,
G.
J.,
Williams,
T.
K.
& Black,
J.
H.
Endovascular Procedures in Patients With Ehlers–Danlos Syndrome: A Review of Clinical Outcomes and Iatrogenic Complications. Ann.
Vasc.
Surg.26,25–33 (2012).
7. Brooke,
B.
S.,
Arnaoutakis,
G.,
McDonnell,
N.
B.
& Black,
J.
H.
Contemporary management of vascular complications associated with Ehlers-Danlos syndrome. J.
Vasc.
Surg.51,131–139 (2010).
8. Sacks,
D.,
McClenny,
T.
E.,
Cardella,
J. F., Lewis,
C.
A.,
Society of Interventional Radiology Clinical Practice Guidelines.
J Vasc Interv Radiol. 14,199–202 (2003).